BioSpace News Archive

Molecular Templates, Inc., announced that the U.S. Food and Drug Administration informed MTEM that it has placed a partial clinical hold on the Phase 1 study of MT-0169 based on previously disclosed cardiac adverse events noted in two patients dosed at 50 mcg/kg that prompted the dose reduction to 5 mcg/kg last year.

A groundbreaking study by a team of scientists at YDS Pharmatech, Inc. has introduced an innovative Generative Diffusion Model for sampling ensembles of degrader-induced ternary interactions, enabling a more effective approach to structure-based optimization of Proteolysis Targeting Chimeras.